RARE
Ultragenyx Pharmaceutical Inc.
Nasdaq · usd
Ultragenyx Pharmaceutical Inc. (RARE) trades at $16.01 (+2.31%) as of 2:51:24 PM EDT on Oct 26, 2026, +10.38% over the past month. Market cap is $1.54B, with 3.1 days to cover in short interest.
Stock performance
How Ultragenyx Pharmaceutical Inc. (RARE) stock has performed from one day to one year, with its 52-week range.
- 1D
- +2.27%
- 1W
- +6.20%
- 1M
- +10.38%
- YTD
- -30.41%
- 1Y
- -54.67%
- 52-wk range
- $12.73 – $39.89
Key statistics
Today's trading snapshot for RARE: day range, open, previous close, volume and market cap.
- Day range
- $15.59 – $16.22
- Open
- $15.75
- Prev close
- $15.65
- Volume
- 1.68M
- Market cap
- $1.54B
- Shares out
- 98.59M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Ultragenyx Pharmaceutical Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 2.15
- P/B
- -5.30
- P/FCF
- —
- ROE
- 201.4%
- ROA
- -46.4%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Ultragenyx Pharmaceutical Inc. has disclosed to the SEC on Form 8-K.
- Settlement agreementOct 19, 2026
On October 19, 2026, Ultragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Navinta LLC resolving patent litigation related to patents covering the Company's DOJOLVI® (triheptanoin) oral liquid.
- Regulatory decisionOct 14, 2026
The Company was awarded the PRV by the U.S. Food and Drug Administration ("FDA") on September 17, 2026 upon approval of FAYUVITM (rebisufligene etisparvovec-hopf) also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).
- Regulatory decisionOct 7, 2026
The Company was awarded the PRV by the U.S. Food and Drug Administration ("FDA") on August 19, 2026 upon approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa).
- Product or service launchSep 17, 2026
FAYUVI is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A, a progressive and fatal neurodegenerative disease, and the second gene therapy approval for Ultragenyx.
- Clinical trial resultsSep 2, 2026
The study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index ("MDRI"). The safety profile observed in Aspire was consistent with Phase 1/2.
RARE short interest
How heavily RARE is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.1
- Short interest
- 20.35M
- Avg volume
- 6.5M
As of · reported to FINRA twice monthly.
RARE news
The latest news and headlines about Ultragenyx Pharmaceutical Inc. (RARE).
- RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekpositiveZacks Investment Research· Oct 15, 2026
- Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?neutralZacks Investment Research· Oct 14, 2026
- Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashpositiveZacks Investment Research· Oct 8, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc. - OSISnegativeGlobeNewswire Inc.· Oct 6, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREnegativeGlobeNewswire Inc.· Oct 6, 2026
Frequently asked questions
What is the Ultragenyx Pharmaceutical Inc. (RARE) stock price today?
Ultragenyx Pharmaceutical Inc. (RARE) is trading at $16.01 (+2.31% on the day) as of 2:51:24 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions.
What is the short interest in RARE?
As of Sep 30, 2026, RARE has 20.35M shares short and 3.1 days to cover.
What exchange is RARE listed on?
Ultragenyx Pharmaceutical Inc. (RARE) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of RARE with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a RARE analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.